Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with an endoscopically confirmed diagnosis of active moderate to severe Ulcerative colitis (UC).
Participants initiating Upadacitinib (UPA) at the investigator's discretion as part of their routine clinical care; the decision to administer UPA must be made prior to and independent of documentation for the study and according to the approved local label.
Participants able to understand and communicate with the investigator and comply with the requirements of the study.
Participants willing to continue with study documentation after cessation of UPA.
You may not be if
Participants with any contraindication to Upadacitinib (UPA).
Participants previously exposed to a Janus kinase (JAK) inhibitor.
Clareo Health | Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
